Insmed Shares Leap After Q2 Results and Bullish Brinsupri Guidance
Insmed shares jumped 19.2% in pre-market trading after the company reported second-quarter 2026 results that outpaced analyst expectations on both revenue and EPS. Total revenue reached $425.5 million, led by Brinsupri sales of $309.2 million, and the company posted a near-breakeven net loss of $0.06 per share. Management raised full-year Brinsupri…